Vancouver, Canada — December 24, 2025 — Leads & Copy — Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company, reflected on a year of progress in advancing its lead candidate, CMND-100, for the treatment of Alcohol Use Disorder (AUD).
Throughout 2025, Clearmind achieved milestones in its FDA-approved Phase I/IIa clinical trial for CMND-100, a non-hallucinogenic MEAI-based oral compound designed to address AUD.
Key highlights of the year included the advancement of the multinational Phase I/IIa trial with site activations at Yale School of Medicine, Johns Hopkins University School of Medicine, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center. The company initiated first-in-human dosing, completed treatment and enrollment for the first cohort, and reported positive top-line safety and tolerability results with no serious adverse events. The first patients in the Israeli sites were enrolled and successfully dosed. Enrollment and dosing for the second cohort was also completed.
Clearmind received unanimous approval from the Data and Safety Monitoring Board (DSMB) to continue the Phase I/IIa clinical trial following an interim review.
The company also strengthened its intellectual property portfolio and pipeline of its non-hallucinogenic neuroplastogen patents with multiple international patent filings and publications targeting indications such as weight loss, obesity, metabolic disorders, depression, PTSD, anxiety and binge behaviors.
Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine, said that 2025 has been a pivotal year for Clearmind as it transitioned into a clinical-stage company, executing on its multinational trial. Zuloff-Shani added that these achievements underscore the company’s disciplined approach to innovation and its commitment to delivering transformative treatments for addictions and mental health challenges.
Clearmind remains focused on advancing its pipeline, generating additional clinical data, and exploring strategic opportunities to maximize shareholder value and patient impact in 2026.
Clearmind is focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. The Company’s intellectual portfolio currently consists of nineteen patent families, including 31 granted patents.
Shares of Clearmind are listed for trading on Nasdaq under the symbol “CMND” and the Frankfurt Stock Exchange under the symbol “CWY0.”
Investor Relations
invest@clearmindmedicine.com
Telephone: (604) 260-1566
US: CMND@crescendo-ir.com
General Inquiries
Info@Clearmindmedicine.com
Source: Clearmind Medicine Inc.
